Raehan Satya Deanasa

Mr. Raehan Satya Deanasa

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2023 in Narra J
Verified
Journal Article
Open access
PDF file
ASArya M. Simanjuntak
Arya M. Simanjuntak
RDRaehan Satya Deanasa
Raehan Satya Deanasa
PAPutri M. Afladhanti
Putri M. Afladhanti
IYIndra Yovi
Indra Yovi
SSSuyanto Suyanto
Suyanto Suyanto
DRDani Rosdiana
Dani Rosdiana
Concerns regarding the rise of drug-resistant tuberculosis (DR-TB) infections and the need for new drugs with shorter treatment time and fewer side effects have been voiced by the World Health Organization (WHO). The WHO revised its guideline to treat multi-drug resistant tuberculosis (MDR-TB) with a 6-month course of BPaLM (bedaquiline, pretomanid, linezolid and moxifloxacin) in 2022. However, a thorough study and meta-analysis of available evidence is required due to the limited confidence of the evidence confirming the effectiveness of pretomanid-containing regiments. The aim of this systematic review and meta-analysis was to evaluate the effectiveness of pretomanid-containing regiments in treating DR-TB patients. Data from six search engines were searched using inclusion criteria based on the PICOS framework. The keywords of pretomanid and tuberculosis or their alternatives were used. Using RoB2 Cochrane risk-of-bias tool for randomized clinical trials, data were independently extracted and the quality of the data was evaluated. Odds ratio (OR) and heterogeneity tests were used and the findings were presented in ORs and forest plots. A total of four studies with 237 patients was included in the final analysis and 204 (86%) patients had favorable outcome (cured) and 33 (14%) was not cured. Pretomanid-containing regimen (OR: 46.73; 95%CI: 11.76–185.7) and BPaLM/BPaL (OR: 41.67; 95%CI: 8.86–196.73) regimens were associated with favorable outcome (cured). This meta-analysis indicates that the pretomanid-containing regimen and the BPaLM/BPaL regimen could increase the chance to have favorable outcome in DR-TB patients.

26 April 2024 in Pneumon
Verified
Journal Article
Open access
RDRaehan Satya Deanasa
Raehan Satya Deanasa
ASArya Marganda Simanjuntak
Arya Marganda Simanjuntak
FSFara Syafira
Fara Syafira
PAPutri Mahirah Afladhanti
Putri Mahirah Afladhanti
AHAnisa Hawari
Anisa Hawari
NRNur Riviati
Nur Riviati
Introduction: Newer regimens are needed and expected to have a shorter therapeutic time to increase drug adherence to completion in drug sensitive tuberculosis (DS-TB) patients. Methods: We conducted first a systematic review and meta-analysis of prior studies to evaluate the effectiveness...

28 December 2022 in Indonesian Journal of Cancer
Verified
Journal Article
Open access
PDF file
RDRaehan Satya Deanasa
Raehan Satya Deanasa
MUMulawan Umar
Mulawan Umar
AFAgita Diora Fitri
Agita Diora Fitri
Background: There is still a limited number of studies related to overall survival in breast cancer patients in Indonesia. This study determines the overall survival and the factor which can affect the survival of stage III breast cancer patients.Methods: This study was a retrospective study. Patients first diagnosed with stage III breast cancer from January 1 to August 31, 2018, at DR. Mohammad Hoesin General Hospital Palembang had been studied. The primary outcome of this study was overall survival. The sociodemographic, clinicopathology, and treatment factors were analyzed to identify the independent variables associated with overall survival using Kaplan-Meier and Cox proportional hazard regression.Results: In this study, 78 samples were included. The 3-year overall survival for stage III breast cancer was 71%. In the bivariate analysis, several factors including older age (> 40) (HR = 2.795, 95% CI 1.223—6.387), higher stages for IIIB (HR = 7.155, 95% CI 0.960—53.334), and IIIC (HR = (HR = 33.450, 95% CI 3.013-371.354), history of not undergoing surgical intervention (HR = 3.999, 95% CI 1.684—9.495), and adjuvant chemotherapy (HR = 2.768, 95% CI 1.211—6.327) have been associated significantly to lower overall survival. Multivariate analysis showed IIIC breast cancer stage as an independent factor and had a significantly increased probability of mortality (HR = 14.677, 95% CI 1.268—169.948).Conclusions: The stage at diagnosis was the only significant predictor for the survival outcome, indicating that early diagnosis may need more attention.

30 June 2026 in Jurnal Administrasi Kesehatan Indonesia
Verified
Journal Article
Open access
PDF file
RDRaehan Satya Deanasa
Raehan Satya Deanasa
FIFachmi Idris
Fachmi Idris
MAMuhammad Aziz
Muhammad Aziz
Background: Adherence to the medication of Jaminan Kesehatan Nasional (JKN) patients in Indonesia was revealed to be suboptimal (<50%) compared to other developed countries. The government initiative to address this issue is through the Chronic Disease Management Program (PROLANIS), with the main focus on hypertension and type 2 Diabetes Aims: This systematic review aimed to determine the factors influencing the adherence of JKN members in PROLANIS. Methods: Relevant studies were searched from PubMed, Science Direct, Epistemonikos, Proquest, Cochrane, Google Scholar, and Garuda. All accessible studies in the last 10 years and written in English or Indonesian are included. Applying PRISMA 2020 guidelines, 13 peer-reviewed papers satisfied the inclusion and exclusion criteria. The risk of bias was determined with JBI critical appraisal tools. Results: Most of the study scored more than 76.9%. The prevalence of adherence ranged from 19.2 to 75.5%. Socioeconomic f and patient factors of the disease were revealed to influence medication adherence among the reviewed studies consistently. Conclusion: Decision-makers and health providers should consider all these factors when developing health policies or interventions to promote PROLANIS patient adherence. A further study assessing adherence with a standardized assessment to understand all necessary influencing factors comprehensively needs to be conducted Keywords: Adherence, chronic disease, JKN, medication, PROLANIS

31 March 2023 in Althea Medical Journal
Verified
Journal Article
Open access
PDF file
RDRaehan Satya Deanasa
Raehan Satya Deanasa
AZAlifa Alya Zalfa
Alifa Alya Zalfa
NPNurul Mufliha Patahuddin
Nurul Mufliha Patahuddin
LZLathifah Dzakiyyah Zulfa
Lathifah Dzakiyyah Zulfa
SHSofia Hana
Sofia Hana
RSRizma Adila Syakurah
Rizma Adila Syakurah
Background: Hypertension is the most common comorbid disease which can cause further complications in COVID-19 patients. On the contrary, the pandemic has also caused lower health services and adherence to hypertension therapy. This study aimed to examine the impact of the COVID-19 pandemic on medication adherence in people with hypertension in Indonesia.Methods: The research was conducted using an analytical quantitative method. Patients with hypertension from seven islands across Indonesia were recruited based on eligibility criteria during Bulan Bakti 2021, a social outreach by Ikatan Senat Mahasiswa Kedokteran Indonesia about basic health across Indonesia. The demographic and medication history of the respondents were recorded. The Indonesian version of the Morisky Medication Adherence Scale (MMAS-8) questionnaire was distributed, and the medication adherence level was assessed.Results: A total of 1155 patients, mainly females (62.2%) participated in this study. More than half of the patients had low adherence (55.25%). Males (Adjusted Odd Ratio (AOR) 0.777 [CI 95% 0.529–1.019]), employed (AOR 0.857 [CI 95% 0.495–1.483]), higher income (AOR 0.522 [CI 95% 0.393–0.713]), and those who had information from healthcare worker (AOR 0.583 [CI 95% 0.361–0.878]) were found to have better medication adherence in multivariate logistic regression test.Conclusion: Medication adherence level in patients with hypertension during the pandemic is markedly low. Integrated preventive and promotive measures, especially from healthcare workers, are needed to prevent further morbidity and mortality.Â